Category Archives: BRICS

Breaking news for access to biological medicines – Brazilian court nixes biological drug eculizumab patent, says more could follow

Source: BioCentury | April 21, 2018 A Brazilian court unanimously ruled Friday to remove patent protection for Soliris eculizumab from Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), opening the door for production of biosimilar versions in the country. In a statement, Brazil’s Attorney General Office said … Continue reading

Posted in Access to Medicins, Brazil Patent Reform, Open access, Patent, Regulation | Leave a comment

Moment of truth for global TB response

On Thursday 16 November 2017, Russian president Vladimir Putin told a hall full of health ministers in Moscow that TB is a “serious problem”, and said, “I am confident that the only way we can stand up against this truly global threat … Continue reading

Posted in BRICS, R&D, Tuberculosis (TB), Uncategorized | Leave a comment

BRICS roots for affordable medicines

Public health targets should be placed above trade deals, says J.P. Nadda By Vidya Krishnan, The Hindu | December 17, 2016 Union Health Minister J.P. Nadda has pressed for public health targets to be placed above trade deals. “Trade regimes … Continue reading

Posted in BRICS, TRIPS plus, Uncategorized | Leave a comment

Speak up for affordable medicine

Iol news, Nobember 19, 2015. US and European pharmaceutical industries see South Africa as “ground zero” for keeping their large profit margins, say Julia Hill and Catherine Tomlinson. 

Posted in BRICS, Fix the patent law, Pricing, South Africa's Patent Act | Leave a comment

Tackling Antimicrobial Resistance Is an Area BRIC Countries Can Lead the World – They Must Take This Opportunity

Huffington Post; November 12, 2015. Brazil, India, Russia and China have gone through a period of rapid economic development, making them important global players in the 21st century. However, they are also the countries that might be affected most severely by growing antimicrobial … Continue reading

Posted in Antibiotics, BRICS, Innovation | Leave a comment

US pharma gets a booster shot

Source: Business Line Thanks to the India-US Intellectual Property Working Group. Here’s how — and why this is bad news for India’s poor Prime Minister Narendra Modi’s first official visit to the US included several meetings with industry representatives and … Continue reading

Posted in BRICS, Compulsory Licensing, FDI, Generics, Innovation, IP Rights, IPR policy, Patent examination system, Patent Term Extension, Pricing, US pressure on India, USTR 301 report, WTO | Tagged , , | Leave a comment

The Op-Ed: What Patent Reform In Brazil And South Africa Can Mean

Source: Pharmalot In recent months, two countries with large economies and large populations both took steps to rework their patent laws, in part, to expand access to medicines. The moves come amid increasing concerns that treatments for certain ailments, such … Continue reading

Posted in Brazil Patent Reform, Doha Declaration, Draft South Africa Policy on IP 2013, Generics, HIV/Aids, IP Rights, IPR Enforcement, Patents, Right to Health, TRIPS, TRIPS flexibilities, Voluntary License, WTO | Tagged | Leave a comment